These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32184965)

  • 1. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.
    Rajapaksa NS; Gobbi A; Drobnick J; Do S; Kolesnikov A; Liang J; Chen Y; Sujatha-Bhaskar S; Huang Z; Brightbill H; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR; Bryan MC
    ACS Med Chem Lett; 2020 Mar; 11(3):327-333. PubMed ID: 32184965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
    Chen Y; Singh R; Lin N; Taylor V; Masuda ES; Payan DG
    ACS Med Chem Lett; 2022 Apr; 13(4):714-719. PubMed ID: 35450353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IRAK4 for Degradation with PROTACs.
    Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA
    ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.
    Seganish WM; Fischmann TO; Sherborne B; Matasi J; Lavey B; McElroy WT; Tulshian D; Tata J; Sondey C; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Aug; 6(8):942-7. PubMed ID: 26288698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of human IRAK1.
    Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
    ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.
    Cumming IA; Degorce SL; Aagaard A; Braybrooke EL; Davies NL; Diène CR; Eatherton AJ; Felstead HR; Groombridge SD; Lenz EM; Li Y; Nai Y; Pearson S; Robb GR; Scott JS; Steward OR; Wu C; Xue Y; Zhang L; Zhang Y
    Bioorg Med Chem; 2022 Jun; 63():116729. PubMed ID: 35439688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
    Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
    J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.